The report provides a comprehensive overview of the UK independent healthcare and social care sectors, including data on market value, capacity, trends, leading players, funding sources, and key issues. It highlights the role of private payers and independent sector providers, alongside the public sector, in the funding and delivery of UK health and care services.

Centene Corporation is set to report its second-quarter 2024 results. The company's performance is expected to have benefited from enhanced volumes and contributions from its Commercial business, but declining total memberships and growing cost ratio might affect second-quarter profits.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Telsey Advisory Group cut the price target for Big Lots, Inc. (NYSE:BIG) from $5 to $2.5. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Big Lots shares dipped 18.2% to close at $2.88 on Thursday. See how other analysts view this stock. Oppenheimer raised the price target for Addus HomeCare Corporation (NASDAQ:ADUS) from $118 to $130. Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating. Addus HomeCare shares rose 1.2% to close at $116.07 on Thursday. See how other analysts view this stock. Oppenheimer increased Microsoft Corporation (NASDAQ:MSFT) price target from $450 to $500. Oppenheimer analyst Timothy Horan maintained an Outperform rating. Microsoft shares gained 0.1% to close at $424.52 on Thursday. See how other analysts view this stock. B of A Securities ...Full story available on Benzinga.com

Addus HomeCare (NASDAQ:ADUS) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 1 1 0 Last 30D 0 1 0 0 0 1M Ago 2 1 0 0 0 2M Ago 0 0 0 1 0 3M Ago 0 1 1 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $109.86, a high estimate of $128.00, and a low estimate of $83.00. A decline of 4.05% from the prior average price target is evident in the current average. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Addus HomeCare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Scott Fidel Stephens & Co. Raises Overweight $128.00 $120.00 Ryan Langston TD Cowen Raises Buy $119.00 $105.00 Scott Fidel Stephens & Co. Maintains Overweight $115.00 - Joanna Gajuk B of A Securities Raises Buy $118.00 $115.00 Andrew Mok Barclays Announces Underweight $83.00 - Michael Wiederhorn Oppenheimer Maintains Outperform $118.00 $118.00 Andrew Mok Barclays Announces Equal-Weight $88.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ...Full story available on Benzinga.com

DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.

We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.

The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 10% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ADUS vs. USPH: Which Stock Is the Better Value Option?

Here is how Addus HomeCare (ADUS) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

In the preceding three months, 4 analysts have released ratings for Addus HomeCare (NASDAQ:ADUS), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 1 1 0 Last 30D 0 0 0 1 0 1M Ago 0 1 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $97.75, a high estimate of $118.00, and a low estimate of $83.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.16%. Decoding Analyst Ratings: A Detailed Look The standing of Addus HomeCare among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Mok Barclays Announces Underweight $83.00 - Michael Wiederhorn Oppenheimer Maintains Outperform $118.00 $118.00 Andrew Mok Barclays Announces Equal-Weight $88.00 - Ben Hendrix RBC Capital Maintains Outperform $102.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company. Rating: Delving into assessments, analysts ...Full story available on Benzinga.com

ADUS vs. USPH: Which Stock Is the Better Value Option?